ARS Pharmaceuticals Inc. Common Stock (NASDAQ: SPRY)
58 Days left to seek lead plaintiff status.
The complaint alleges defendants provided investors with material information concerning ARS’s expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Defendants’ statements included, among other things, confidence that this coverage would begin on July 1, 2026 and be in place for the summer and back-to-school allergy seasons.